The gene dosage of class Ia PI3K dictates the development of PTEN hamartoma tumor syndrome

Cell Cycle

Volumn 12, Issue 23, 2013, Pages 3589-3593

  Wang, Qi ^a,b   Weisberg, Ellen ^a   Zhao, Jean J ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

PI3K inhibitor; PI3K isoforms; PTEN; PTEN hamartoma tumor syndrome; Skin disease

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; BUPARLISIB; ISOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P110 ALPHA; PROTEIN P110 BETA; UNCLASSIFIED DRUG;

ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST EPITHELIUM; BREAST LESION; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FEMALE; GENE DELETION; GENE DOSAGE; GENE LOSS; GENOTYPE; HAMARTOMA; HOMEOSTASIS; KERATINOCYTE; MAMMARY GLAND; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN PHOSPHORYLATION; PTEN HAMARTOMA TUMOR SYNDROME; SKIN TUMOR; SKINFOLD THICKNESS; UPREGULATION;

PI3K INHIBITOR; PI3K ISOFORMS; PTEN; PTEN HAMARTOMA TUMOR SYNDROME; SKIN DISEASE;

ALLELES; AMINOPYRIDINES; ANIMALS; BREAST NEOPLASMS; CLASS IA PHOSPHATIDYLINOSITOL 3-KINASE; DISEASE MODELS, ANIMAL; FEMALE; GENE DOSAGE; GENOTYPE; HAMARTOMA SYNDROME, MULTIPLE; MICE; MORPHOLINES; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; SKIN NEOPLASMS;

EID: 84890246644     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.26812     Document Type: Article

References (40)

1. Salmena L, Carracedo A, Pandolfi PP. Tenets of PTEN tumor suppression. Cell 2008; 133:403-14; PMID:18455982; http://dx.doi.org/10.1016/j.cell.2008.04. 013
2. Sulis ML, Parsons R. PTEN: from pathology to biology. Trends Cell Biol 2003; 13:478-83; PMID:12946627; http://dx.doi.org/10.1016/S0962-8924(03)00175-2
3. Hobert JA, Eng C. PTEN hamartoma tumor syndrome: an overview. Genet Med 2009; 11:687-94; PMID:19668082; http://dx.doi.org/10.1097/GIM.0b013e3181ac9aea
4. Blumenthal GM, Dennis PA. PTEN hamartoma tumor syndromes. Eur J Hum Genet 2008; 16:1289-300; PMID:18781191; http://dx.doi.org/10.1038/ ejhg.2008.162
5. Gustafson S, Zbuk KM, Scacheri C, Eng C. Cowden syndrome. Semin Oncol 2007; 34:428-34; PMID:17920899; http://dx.doi.org/10.1053/j. seminoncol.2007.07.009
6. Liaw D, Marsh DJ, Li J, Dahia PL, Wang SI, Zheng Z, Bose S, Call KM, Tsou HC, Peacocke M, et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 1997; 16:64-7; PMID:9140396; http://dx.doi.org/10.1038/ng0597-64
7. Schrager CA, Schneider D, Gruener AC, Tsou HC, Peacocke M. Clinical and pathological features of breast disease in Cowden's syndrome: an underrecognized syndrome with an increased risk of breast cancer. Hum Pathol 1998; 29:47-53; PMID:9445133; http://dx.doi.org/10.1016/S0046-8177(98)90389-6
8. Saslow D, Boetes C, Burke W, Harms S, Leach MO, Lehman CD, Morris E, Pisano E, Schnall M, Sener S, et al.; American Cancer Society Breast Cancer Advisory Group. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 2007; 57:75-89; PMID:17392385; http://dx.doi.org/10.3322/canjclin.57.2.75
9. Riegert-Johnson DL, Gleeson FC, Roberts M, Tholen K, Youngborg L, Bullock M, Boardman LA. Cancer and Lhermitte-Duclos disease are common in Cowden syndrome patients. Hered Cancer Clin Pract 2010; 8:6; PMID:20565722; http://dx.doi.org/10.1186/1897-4287-8-6
10. Krymskaya VP, Goncharova EA. PI3K/mTORC1 activation in hamartoma syndromes: therapeutic prospects. Cell Cycle 2009; 8:403-13; PMID:19177005; http://dx.doi.org/10.4161/cc.8.3.7555
11. Squarize CH, Castilho RM, Gutkind JS. Chemoprevention and treatment of experimental Cowden's disease by mTOR inhibition with rapamycin. Cancer Res 2008; 68:7066-72; PMID:18757421; http://dx.doi.org/10.1158/0008-5472.CAN-08-0922
12. Lee L, Sudentas P, Donohue B, Asrican K, Worku A, Walker V, Sun Y, Schmidt K, Albert MS, El-Hashemite N, et al. Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models. Genes Chromosomes Cancer 2005; 42:213-27; PMID:15578690; http://dx.doi.org/10.1002/gcc.20118
13. Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM, Schmithorst VJ, Laor T, Brody AS, Bean J, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 2008; 358:140-51; PMID:18184959; http://dx.doi.org/10.1056/NEJMoa063564
14. Krueger DA, Care MM, Holland K, Agricola K, Tudor C, Mangeshkar P, Wilson KA, Byars A, Sahmoud T, Franz DN. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 2010; 363:1801-11; PMID:21047224; http://dx.doi.org/10.1056/NEJMoa1001671
15. Major P. Potential of mTOR inhibitors for the treatment of subependymal giant cell astrocytomas in tuberous sclerosis complex. Aging (Albany NY) 2011; 3:189-91; PMID:21415462
16. Carracedo A, Pandolfi PP. The PTEN-PI3K pathway: of feedbacks and cross-talks. Oncogene 2008; 27:5527-41; PMID:18794886; http://dx.doi.org/10. 1038/onc.2008.247
17. Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J, Zhu S, Hsueh T, Chen Y, Wang W, Youngkin D, et al. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med 2008; 5:e8; PMID:18215105; http://dx.doi.org/10.1371/journal.pmed.0050008
18. Cully M, You H, Levine AJ, Mak TW. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 2006; 6:184-92; PMID:16453012; http://dx.doi.org/10.1038/nrc1819
19. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009; 8:627-44; PMID:19644473; http://dx.doi.org/10.1038/nrd2926
20. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2:489-501; PMID:12094235; http://dx.doi.org/10.1038/nrc839
21. Jia S, Liu Z, Zhang S, Liu P, Zhang L, Lee SH, Zhang J, Signoretti S, Loda M, Roberts TM, et al. Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature 2008; 454:776-9; PMID:18594509
22. Guillermet-Guibert J, Bjorklof K, Salpekar A, Gonella C, Ramadani F, Bilancio A, Meek S, Smith AJ, Okkenhaug K, Vanhaesebroeck B. The p110beta isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110gamma. Proc Natl Acad Sci U S A 2008; 105:8292-7; PMID:18544649; http://dx.doi.org/10.1073/pnas.0707761105
23. Ciraolo E, Morello F, Hobbs RM, Wolf F, Marone R, Iezzi M, Lu X, Mengozzi G, Altruda F, Sorba G, et al. Essential role of the p110beta subunit of phosphoinositide 3-OH kinase in male fertility. Mol Biol Cell 2010; 21:704-11; PMID:20053680; http://dx.doi.org/10.1091/mbc.E09-08-0744
24. Graupera M, Guillermet-Guibert J, Foukas LC, Phng LK, Cain RJ, Salpekar A, Pearce W, Meek S, Millan J, Cutillas PR, et al. Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration. Nature 2008; 453:662-6; PMID:18449193; http://dx.doi.org/10.1038/nature06892
25. Zhao JJ, Cheng H, Jia S, Wang L, Gjoerup OV, Mikami A, Roberts TM. The p110alpha isoform of PI3K is essential for proper growth factor signaling and oncogenic transformation. Proc Natl Acad Sci U S A 2006; 103:16296-300; PMID:17060635; http://dx.doi.org/10.1073/pnas.0607899103
26. Jia S, Roberts TM, Zhao JJ. Should individual PI3 kinase isoforms be targeted in cancer? Curr Opin Cell Biol 2009; 21:199-208; PMID:19200708; http://dx.doi.org/10.1016/j.ceb.2008.12.007
27. Ni J, Liu Q, Xie S, Carlson C, Von T, Vogel K, Riddle S, Benes C, Eck M, Roberts T, et al. Functional characterization of an isoform-selective inhibitor of PI3Kp110β as a potential anticancer agent. Cancer Discov 2012; 2:425-33; PMID:22588880; http://dx.doi.org/10.1158/2159-8290.CD-12-0003
28. Wee S, Wiederschain D, Maira SM, Loo A, Miller C, deBeaumont R, Stegmeier F, Yao YM, Lengauer C. PTEN-deficient cancers depend on PIK3CB. Proc Natl Acad Sci U S A 2008; 105:13057-62; PMID:18755892; http://dx.doi.org/10.1073/pnas. 0802655105
29. Wang Q, Von T, Bronson R, Ruan M, Mu W, Huang A, Maira SM, Zhao JJ. Spatially distinct roles of class Ia PI3K isoforms in the development and maintenance of PTEN hamartoma tumor syndrome. Genes Dev 2013; 27:1568-80; PMID:23873941; http://dx.doi.org/10.1101/gad.216069.113
30. Alimonti A, Carracedo A, Clohessy JG, Trotman LC, Nardella C, Egia A, Salmena L, Sampieri K, Haveman WJ, Brogi E, et al. Subtle variations in Pten dose determine cancer susceptibility. Nat Genet 2010; 42:454-8; PMID:20400965; http://dx.doi.org/10.1038/ng.556
31. Carracedo A, Alimonti A, Pandolfi PP. PTEN level in tumor suppression: how much is too little? Cancer Res 2011; 71:629-33; PMID:21266353; http://dx.doi.org/10.1158/0008-5472.CAN-10-2488
32. Blanpain C, Fuchs E. Epidermal homeostasis: a balancing act of stem cells in the skin. Nat Rev Mol Cell Biol 2009; 10:207-17; PMID:19209183; http://dx.doi.org/10.1038/nrm2636
33. Li G, Robinson GW, Lesche R, Martinez-Diaz H, Jiang Z, Rozengurt N, Wagner KU, Wu DC, Lane TF, Liu X, et al. Conditional loss of PTEN leads to precocious development and neoplasia in the mammary gland. Development 2002; 129:4159-70; PMID:12163417
34. Jonkers J, Meuwissen R, van der Gulden H, Peterse H, van der Valk M, Berns A. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet 2001; 29:418-25; PMID:11694875; http://dx.doi.org/10.1038/ng747
35. Mikaelian I, Hovick M, Silva KA, Burzenski LM, Shultz LD, Ackert-Bicknell CL, Cox GA, Sundberg JP. Expression of terminal differentiation proteins defines stages of mouse mammary gland development. Vet Pathol 2006; 43:36-49; PMID:16407485; http://dx.doi.org/10.1354/vp.43-1-36
36. Smith GH, Mehrel T, Roop DR. Differential keratin gene expression in developing, differentiating, preneoplastic, and neoplastic mouse mammary epithelium. Cell Growth Differ 1990; 1:161-70; PMID:1707299
37. Lesche R, Groszer M, Gao J, Wang Y, Messing A, Sun H, Liu X, Wu H. Cre/loxP-mediated inactivation of the murine Pten tumor suppressor gene. Genesis 2002; 32:148-9; PMID:11857804; http://dx.doi.org/10.1002/gene.10036
38. Dlugosz AA, Glick AB, Tennenbaum T, Weinberg WC, Yuspa SH. Isolation and utilization of epidermal keratinocytes for oncogene research. Methods Enzymol 1995; 254:3-20; PMID:8531694; http://dx.doi.org/10.1016/0076-6879(95)54003-2
39. Utermark T, Rao T, Cheng H, Wang Q, Lee SH, Wang ZC, Iglehart JD, Roberts TM, Muller WJ, Zhao JJ. The p110α and p110β isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis. Genes Dev 2012; 26:1573-86; PMID:22802530; http://dx.doi.org/10.1101/gad.191973.112
40. Maira SM, Pecchi S, Huang A, Burger M, Knapp M, Sterker D, Schnell C, Guthy D, Nagel T, Wiesmann M, et al. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. Mol Cancer Ther 2012; 11:317-28; PMID:22188813; http://dx.doi.org/10.1158/1535-7163.MCT-11- 0474